Free Trial

Ascendis Pharma A/S (ASND) News Today

$123.19
-1.40 (-1.12%)
(As of 06/18/2024 ET)
Ascendis Pharma A/S logo with Medical background
Goldman Sachs Group Inc. Boosts Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)
Goldman Sachs Group Inc. grew its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 422,854 shares of the biotechnology company's stock after purchasing an additional 12,881 shares
Ascendis Pharma A/S logo with Medical background
Wellington Management Group LLP Decreases Stake in Ascendis Pharma A/S (NASDAQ:ASND)
Wellington Management Group LLP lowered its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 85.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,248,293 shares of the biotechnology company's stock after selling 18,663,
Ascendis Pharma A/S logo with Medical background
Perceptive Advisors LLC Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)
Perceptive Advisors LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 132,176 shares of the
Ascendis Pharma A/S (NASDAQ:ASND) Shares Down 4.4%
Ascendis Pharma A/S logo with Medical background
ADAR1 Capital Management LLC Purchases Shares of 45,884 Ascendis Pharma A/S (NASDAQ:ASND)
ADAR1 Capital Management LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 45,884 shares of the biotechnology company's stock, valued
Ascendis Pharma A/S logo with Medical background
Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Down 4.4%
Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Down 4.4%
Ascendis Pharma A/S logo with Medical background
Sei Investments Co. Has $45.57 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)
Sei Investments Co. lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 8.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 361,830 shares of the biotechnology company's stock after selling 34
Ascendis Pharma A/S logo with Medical background
Avoro Capital Advisors LLC Increases Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)
Avoro Capital Advisors LLC raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,755,555 shares of the biotechnology company's stock after buying an additional 85,55
Ascendis Pharma A/S logo with Medical background
Vestal Point Capital LP Acquires Shares of 625,000 Ascendis Pharma A/S (NASDAQ:ASND)
Vestal Point Capital LP acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 625,000 shares of the biotechnology company's stock, valued at approximately $78,719,00
Ascendis Pharma A/S logo with Medical background
Seven Eight Capital LP Acquires Shares of 18,636 Ascendis Pharma A/S (NASDAQ:ASND)
Seven Eight Capital LP purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 18,636 shares of the biotechnology company's stock,
Ascendis Pharma A/S logo with Medical background
51,700 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Acquired by Gray Foundation
Gray Foundation purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 51,700 shares of the biotechnolog
Ascendis Pharma A/S logo with Medical background
Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Affinity Asset Advisors LLC
Affinity Asset Advisors LLC decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 56.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,000 shares of the biotechnology company
Ascendis Pharma A/S logo with Medical background
Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Update
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 3,460,000 shares, a decrease of 6.5% from the April 30th total of 3,700,000 shares. Based on an average daily trading volume, of 370,500 shares, the short-interest ratio is currently 9.3 days.
Ascendis Pharma A/S logo with Medical background
Hsbc Holdings PLC Buys New Shares in Ascendis Pharma A/S (NASDAQ:ASND)
Hsbc Holdings PLC purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 111,107 shares of the biotechnolo
Ascendis Pharma A/S logo with Medical background
Evoke Wealth LLC Acquires New Shares in Ascendis Pharma A/S (NASDAQ:ASND)
Evoke Wealth LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 27,069 shares of the biotechnology company's stock, va
Ascendis Pharma A/S logo with Medical background
Trexquant Investment LP Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)
Trexquant Investment LP bought a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 9,868 shares of the biotechnology company's stock, valued at approximately $1,243,000. Other hedge funds
Ascendis Pharma A/S logo with Medical background
Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Rating of "Moderate Buy" from Analysts
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating
Ascendis Pharma A/S logo with Medical background
Artisan Partners Limited Partnership Sells 246,181 Shares of Ascendis Pharma A/S (NASDAQ:ASND)
Artisan Partners Limited Partnership cut its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,749,227 shares of the biotechnology
Ascendis Pharma A/S logo with Medical background
Ascendis Pharma A/S (NASDAQ:ASND) Stock Position Increased by Westfield Capital Management Co. LP
Westfield Capital Management Co. LP grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,030,634 sh
Ascendis Pharma A/S logo with Medical background
Ascendis Pharma A/S (NASDAQ:ASND) Raised to "Hold" at StockNews.com
StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Thursday.
Ascendis Pharma A/S logo with Medical background
Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Up 7%
Ascendis Pharma A/S (NASDAQ:ASND) Trading 7% Higher
Ascendis Pharma A/S (NASDAQ:ASND) is Matisse Capital's 5th Largest Position
Matisse Capital grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 31.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,635 shares of the biotechnology com
151,587 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by First Turn Management LLC
First Turn Management LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 151,587 shares of the biotechnology compan
Cantor Fitzgerald Reiterates Overweight Rating for Ascendis Pharma A/S (NASDAQ:ASND)
Cantor Fitzgerald reiterated an "overweight" rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a report on Wednesday.
TimesSquare Capital Management LLC Lowers Position in Ascendis Pharma A/S (NASDAQ:ASND)
TimesSquare Capital Management LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 5.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 792,945 shares of the biotechnology company's stock a
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $262.00 at Wells Fargo & Company
Wells Fargo & Company increased their price objective on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an "overweight" rating in a report on Friday.
Ascendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated an "overweight" rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday.
Ascendis Pharma (spons ADRs) earnings preview: what to expect
Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Up 7.5% in April
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 3,600,000 shares, a growth of 7.5% from the March 31st total of 3,350,000 shares. Based on an average daily volume of 348,900 shares, the short-interest ratio is currently 10.3 days.
Get Ascendis Pharma A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

The asset beating inflation by 4x (Ad)

Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Precious Metals Guide, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.

Click here to get your free copy today.

ASND Media Mentions By Week

ASND Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ASND
News Sentiment

1.18

0.58

Average
Medical
News Sentiment

ASND News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ASND Articles
This Week

4

4

ASND Articles
Average Week

Get Ascendis Pharma A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ASND) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners